- Treatment of uncomplicated influenza, ages ≥ 12 years with symptoms < 48 hours.
- Limitations of use: Consideration should be given to susceptibility patterns for circulating influenza virus strains when deciding whether to use baloxavir because viruses’ changing over time, virus type or subtype, the emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs.
NON-FDA APPROVED USES
- Treatment of influenza in individuals at high risk for influenza-related complications
There's more to see -- the rest of this topic is available only to subscribers.